8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A detailed look at the legal status of compounding empagliflozin (Jardiance), including FDA rules, patent exclusivity, shortage exemptions, and what the current regulatory framework means for patients and prescribers.
A detailed comparison of how the FDA and EMA approved, labeled, and expanded empagliflozin (Jardiance) across type 2 diabetes, heart failure, and chronic kidney disease indications.
A clinical review of empagliflozin (Jardiance) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including Fournier gangrene, ketoacidosis, UTIs, and amputations.
Full FDA approval history for Jardiance (empagliflozin), including original NDA, supplemental approvals for cardiovascular and heart failure indications, label expansions, and post-market safety updates.
A complete guide to Jardiance (empagliflozin) regulatory history worldwide, covering FDA approval dates, label changes, EMA authorization, post-market safety data, and current prescribing guidance.
Every FDA label change for Jardiance (empagliflozin) from 2020 through 2026, including new indications for heart failure, chronic kidney disease, and updated safety warnings.
A complete analysis of Jardiance (empagliflozin) legal disputes, patent challenges, FDA approval history, label expansions, and post-market safety actions from 2014 through 2026.
A clinical review of empagliflozin (Jardiance) regulatory history, current FDA-approved indications, pipeline expansions, and next-generation SGLT2 developments.